DK2298338T3 - Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår - Google Patents

Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår

Info

Publication number
DK2298338T3
DK2298338T3 DK10014943.4T DK10014943T DK2298338T3 DK 2298338 T3 DK2298338 T3 DK 2298338T3 DK 10014943 T DK10014943 T DK 10014943T DK 2298338 T3 DK2298338 T3 DK 2298338T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
skin ulcers
lactoferrin compositions
lactoferrin
Prior art date
Application number
DK10014943.4T
Other languages
English (en)
Inventor
Jose Engelmayer
Atul Varadhachary
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Application granted granted Critical
Publication of DK2298338T3 publication Critical patent/DK2298338T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK10014943.4T 2002-09-16 2003-09-16 Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår DK2298338T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41098102P 2002-09-16 2002-09-16
EP03752398A EP1545587B1 (en) 2002-09-16 2003-09-16 Lactoferrin compositions and methods of diabetic ulcer treatment

Publications (1)

Publication Number Publication Date
DK2298338T3 true DK2298338T3 (da) 2012-09-24

Family

ID=31994228

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10014943.4T DK2298338T3 (da) 2002-09-16 2003-09-16 Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
DK03752398.2T DK1545587T3 (da) 2002-09-16 2003-09-16 Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03752398.2T DK1545587T3 (da) 2002-09-16 2003-09-16 Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår

Country Status (12)

Country Link
US (3) US7524814B2 (da)
EP (2) EP1545587B1 (da)
JP (1) JP4516844B2 (da)
CN (1) CN1694720A (da)
AT (1) ATE497778T1 (da)
AU (2) AU2003270690B2 (da)
CA (1) CA2499014A1 (da)
DE (1) DE60335997D1 (da)
DK (2) DK2298338T3 (da)
ES (1) ES2358645T3 (da)
SI (2) SI1545587T1 (da)
WO (1) WO2004024180A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
DK1507554T3 (da) 2002-05-10 2011-11-21 Agennix Inc Lactoferrin i behandlingen af maligne neoplasmer og andre hyperproliferative sygdomme
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
US7524814B2 (en) * 2002-09-16 2009-04-28 Agennix, Inc. Lactoferrin compositions and methods of wound treatment
AU2003298906A1 (en) * 2002-12-06 2004-06-30 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
ATE426410T1 (de) * 2004-08-20 2009-04-15 Smithkline Beecham Corp Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
ITRM20040638A1 (it) 2004-12-24 2005-03-24 Advance Holdings Ltd Gel piastrinico semisintetico e metodo per la sua preparazione.
US20060240116A1 (en) * 2005-04-22 2006-10-26 David Jolley Bioactive factors in wound healing topical compositions and methods
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US20070059300A1 (en) * 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
CA2630147C (en) * 2005-11-18 2015-08-11 Glanbia Nutritionals (Ireland) Limited Compositions for disrupting and inhibiting reconstitution of wound biofilm
US20070179084A1 (en) * 2006-01-30 2007-08-02 Nation Chiao Tung University Process for reducing the concentration of blood glucose in a diabetic patient
ATE449617T1 (de) * 2006-02-02 2009-12-15 Euro Celtique Sa Hydrogel für wundbehandlung
EP1993592A4 (en) * 2006-02-21 2011-11-16 Ventria Bioscience COMPOSITIONS WITH LACTOFERRIN AND METHOD FOR USE THAT TO AIM IN THE GROWTH OF SKIN CELLS
WO2008003688A1 (en) * 2006-07-03 2008-01-10 Jean-Paul Perraudin Antimicrobial composition and uses thereof
GB0616580D0 (en) * 2006-08-21 2006-09-27 Novathera Ltd Composite material
CA2663417A1 (en) * 2006-09-13 2008-03-20 Southeastern Medical Technologies, Llc Methods and compositions for sealing and adhering biological tissues and medical uses thereof
US10143694B2 (en) * 2006-10-27 2018-12-04 Matthew H. Kopacki Advanced formulations and therapies for treating hard-to-heal wounds
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
WO2009123720A2 (en) * 2008-04-01 2009-10-08 Southeastern Medical Technologies, Llc Methods and compositions for medical articles produced from proteinaceous compounds
EP2141242A1 (en) * 2008-07-04 2010-01-06 Universität des Saarlandes Synthetic pathway enzymes for the production of Argyrins
US8614189B2 (en) * 2008-09-24 2013-12-24 University Of Connecticut Carbon nanotube composite scaffolds for bone tissue engineering
US20110015587A1 (en) * 2009-07-14 2011-01-20 Tumey David M Irrigation Device and Method Using Same
JP2011020973A (ja) * 2009-07-17 2011-02-03 Nrl Pharma Inc 難治性の皮膚潰瘍治療用の医薬組成物、及び、皮膚潰瘍予防用化粧料
CA2778647A1 (en) * 2009-11-25 2011-06-03 Nestec S.A. Nutritional compositions including a high protein component and exogenous nucleotides
CA2798957A1 (en) 2010-05-10 2011-11-17 Lakshmi Sreedharan Nair Lactoferrin-based biomaterials for tissue regeneration and drug delivery
CN103037894A (zh) * 2010-07-01 2013-04-10 华柏恩视觉研究中心 创伤治疗的乳铁蛋白序列、组合物及方法
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US20120171231A1 (en) * 2010-12-29 2012-07-05 Anja Wittke Use of nutritional compositions including lactoferrin in stimulating immune cells
AU2012210013C1 (en) * 2011-01-26 2017-06-01 Megmilk Snow Brand Co., Ltd. Sense-improving agent
EP2670417A4 (en) * 2011-01-31 2014-07-09 Us Army METHODS AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY IRON CHELATORS
WO2013032745A1 (en) * 2011-08-31 2013-03-07 Kci Licensing, Inc. Reduced-pressure treatment and debridement systems and methods
CA2890757C (en) 2012-11-14 2021-10-26 Smith & Nephew, Inc. Stable thermolysin hydrogel
JP6275955B2 (ja) * 2013-04-25 2018-02-07 松尾 敏郎 塩化マグネシウムを摂取する人を除いた生物の細胞の活性化方法
CZ308554B6 (cs) * 2013-10-21 2020-11-25 Univerzita Tomáše Bati ve Zlíně Hydrogelová kosmetická nebo farmaceutická kompozice s účinnějším působením v ní obsažených biologicky aktivních látek z hlediska antimikrobiálních účinků
KR20170086019A (ko) 2014-09-24 2017-07-25 이스티튜토 프로필라티코 이 파르마씨유티코 칸디올리 & 씨. 에스.피.에이. 감염증 및 염증의 예방 및/또는 치료에 유용한 조성물
RU2658707C1 (ru) * 2016-12-28 2018-06-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ восстановления кожного покрова
US20200024329A1 (en) * 2018-07-17 2020-01-23 Bradley G. Thompson Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
KR102316726B1 (ko) * 2018-07-31 2021-10-26 주식회사 레모넥스 상처 치료용 의약 조성물
WO2020121179A1 (en) * 2018-12-11 2020-06-18 Universita' Degli Studi Di Salerno Composition for the treatment of skin lesions
CN110075054A (zh) * 2019-06-06 2019-08-02 山东天源人乳库科技发展有限公司 一种来源于人乳的人源性生长因子修复制剂及其制备方法
BE1027357B1 (nl) * 2019-06-12 2021-01-18 Vanlommel Maria Kristel Voedingssupplement voor versnelde genezing
CN110680949B (zh) * 2019-10-18 2021-06-29 中山大学 一种基于母乳的创伤敷料的制备方法和应用
IL311037A (en) * 2021-08-23 2024-04-01 Lactea Therapeutics Llc Lactoferrin preparations and methods of use
CN113576938B (zh) * 2021-08-26 2022-07-08 广东丸美生物技术股份有限公司 一种口腔护理组合物及其应用
CN116421775A (zh) * 2023-04-21 2023-07-14 青岛优瑞达生物科技有限公司 一种乳铁蛋白凝胶敷料、制备方法和应用
CN116251224B (zh) * 2023-05-16 2023-09-12 江苏正大天创生物工程有限公司 一种乳铁蛋白凝胶敷料及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4788488A (en) * 1986-10-14 1988-11-29 Drexelbrook Controls, Inc. Continuous condition sensing system
US4783488A (en) * 1987-01-31 1988-11-08 Bausch & Lomb Incorporated Contact lens wetting solution
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5705485A (en) 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5849881A (en) 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5198419A (en) 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
KR100196773B1 (ko) * 1990-01-12 1999-06-15 워얼렐 에스. 브로우;도날드 에스. 브로아즈 상처치유 및 조직회복을_향상시키기 위한 조성물
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US6066469A (en) 1990-03-08 2000-05-23 Ferro Dynamics, Inc. Cloning, expression, and uses of human lactoferrin
GB2248842A (en) 1990-10-16 1992-04-22 American Cyanamid Co Film-forming polymer compositions
EP0579830B1 (en) * 1990-11-13 1997-02-05 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal lesion
WO1993000077A1 (en) 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
JP3398957B2 (ja) 1991-12-24 2003-04-21 ザ・プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ Ｄｎａの特定部位の突然変異誘発
EP0559425B1 (en) * 1992-03-02 1999-01-07 Immuno Japan Inc. Use of proteins belonging to the transferrin/lactoferrin family for potentiating the immune system
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
DE4294862T1 (de) * 1992-04-10 1994-06-09 Vni Skij I Medicinskich Polime Pharmazeutische Komposition
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5358706A (en) * 1992-09-30 1994-10-25 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JPH07196529A (ja) * 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd 創傷治癒剤、化粧料および養毛剤
EP1142484A2 (en) 1994-02-16 2001-10-10 Pharming Intellectual Property BV Isolation of lactoferrin from milk
JP3746081B2 (ja) 1994-02-24 2006-02-15 森永乳業株式会社 動物皮膚病治療剤
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US20020016289A1 (en) * 1995-06-01 2002-02-07 Orla M. Conneely Methods for treatment and prevention of helicobacter pylori infection using lactoferrin
US5834424A (en) * 1995-07-12 1998-11-10 Gambit International Limited Use of lactoferrin for therapy of acute of chronic infectious diseases by the intracellular gram-positive pathogens streptococcus pyogenes and staphylococcus aureus
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
US6111081A (en) 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
GB2321191B (en) 1997-01-17 2000-09-27 Johnson & Johnson Medical Peptides for use in wound treatment
US6333311B1 (en) 1997-02-03 2001-12-25 Pharming Useful properties of human lactoferrin and variants thereof
DE69830582T2 (de) 1997-04-10 2006-05-04 Agennix, Inc., Houston Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
JP3856908B2 (ja) * 1997-06-06 2006-12-13 田辺製薬株式会社 褥瘡及び／又は創傷治療剤
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
AU2002302192B2 (en) 2001-06-13 2007-08-16 Zz Biotech Llc Treatment and composition for wound healing
DK1507554T3 (da) 2002-05-10 2011-11-21 Agennix Inc Lactoferrin i behandlingen af maligne neoplasmer og andre hyperproliferative sygdomme
US7238661B2 (en) 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
US7524814B2 (en) * 2002-09-16 2009-04-28 Agennix, Inc. Lactoferrin compositions and methods of wound treatment
WO2004050037A2 (en) 2002-12-04 2004-06-17 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
AU2003298906A1 (en) 2002-12-06 2004-06-30 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
US7592306B2 (en) 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
AU2003293500A1 (en) * 2002-12-12 2004-07-09 Agennix Incorporated Lactoferrin in the reduction of pain
WO2004103285A2 (en) 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects

Also Published As

Publication number Publication date
AU2003270690B2 (en) 2009-07-30
US8030272B2 (en) 2011-10-04
CN1694720A (zh) 2005-11-09
EP1545587A4 (en) 2009-06-17
EP2298338B1 (en) 2012-08-22
US20040142037A1 (en) 2004-07-22
SI1545587T1 (sl) 2011-06-30
AU2009225309A1 (en) 2009-11-05
DK1545587T3 (da) 2011-05-09
WO2004024180A1 (en) 2004-03-25
CA2499014A1 (en) 2004-03-25
EP1545587A1 (en) 2005-06-29
AU2003270690A1 (en) 2004-04-30
JP4516844B2 (ja) 2010-08-04
AU2009225309B2 (en) 2012-06-14
ATE497778T1 (de) 2011-02-15
EP2298338A1 (en) 2011-03-23
EP1545587B1 (en) 2011-02-09
US8247373B2 (en) 2012-08-21
DE60335997D1 (de) 2011-03-24
US20120010150A1 (en) 2012-01-12
JP2006503044A (ja) 2006-01-26
US7524814B2 (en) 2009-04-28
US20090253627A1 (en) 2009-10-08
SI2298338T1 (sl) 2012-11-30
ES2358645T3 (es) 2011-05-12

Similar Documents

Publication Publication Date Title
DK2298338T3 (da) Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
NO20052139L (no) Bandasje og epidermal posisjoneringsmekanisme og fremgangsmate for anvendelse av samme
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
DE60317799D1 (de) Antimikrobielle zusammensetzung und anwendungsverfahren
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
DK1471902T3 (da) Sammensætninger til brug i fremgangsmåder til behandling af høretab
NO20051521D0 (no) Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt
DE60112807D1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE60223576D1 (de) Hautbehandlungszusammensetzung
NO20033123D0 (no) Terapeutisk hinnedannende sammensetning og behandlingsplan derav
NO20042012L (no) Sammensetning og fremgangsmate for behandling av diabetes
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60305300D1 (de) Haarbehandlungszusammensetzungen